0HS8:LSE:LSE-Caladrius Biosciences Inc. (USD)

COMMON STOCK | |

Last Closing

USD 2.96

Change

0.00 (0.00)%

Market Cap

N/A

Volume

600.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Address: 110 Allen Road, Basking Ridge, NJ, United States, 07920

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
0R37:LSE Berkshire Hathaway Inc

+3.00 (+0.66%)

USD 9,223,372,036.85B
0R2T:LSE Micron Technology Inc

N/A

USD 9,223,372,036.85B
0R2F:LSE Wells Fargo & Company

+1.66 (+3.06%)

USD 9,223,372,036.85B
0R2V:LSE Apple Inc.

-3.50 (-1.52%)

USD 9,223,372,036.85B
0R15:LSE SoftBank Group Corp.

+350.13 (+4.10%)

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

+346.00 (+4.52%)

USD 7,596.04B
0M69:LSE OTP Bank Nyrt

N/A

USD 5,014.80B
0KS2:LSE Public Service Enterprise Grou..

+0.11 (+0.12%)

USD 3,886.06B
0K80:LSE NextEra Energy Inc.

-0.58 (-0.69%)

USD 3,840.59B
0KCI:LSE ONEOK Inc.

-5.14 (-5.43%)

USD 3,833.26B

ETFs Containing 0HS8:LSE

HAU-U:CA 3.45 % 0.00 %

N/A

N/A
SDOG ALPS Sector Dividend Dogs.. 2.09 % 0.40 %

+0.55 (+0.94%)

USD 1.23B
RNMC 1.15 % 0.60 %

N/A

N/A
RXI iShares Global Consumer D.. 0.00 % 0.46 %

+4.10 (+0.94%)

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.93% N/A N/A 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.93% N/A N/A 44% F
Trailing 12 Months  
Capital Gain 41.63% N/A N/A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.63% N/A N/A 87% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 123.79% N/A N/A 96% N/A
Dividend Return 123.79% N/A N/A 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 215.75% N/A N/A 10% F
Risk Adjusted Return 57.38% N/A N/A 79% B-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike